Inclusion Criteria:

- EOC patients must be platinum resistant/refractory (see 1.1 for definition) and be
considered by the attending physician capable of being treated in this study
according to GCP.

- Measurable disease by RECIST criteria or evaluable disease by GCIC criteria

- No prior anthracycline or lenalidomide use, unless the dose received was equal or
less than one cycle and the patient did not progress on treatment.

- Subjects must have calculated creatinine clearance > 60ml/min by Cockcroft-Gault
formula during the escalation phase.

- Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault
formula during the expansion phase. See section below, "Dosing Regimen", regarding
lenalidomide dose adjustment for calculated creatinine clearance > 30ml/min and <
60ml/min.

- Understand and voluntarily sign an informed consent form.

- All study participants must be registered into the mandatory RevAssist® program, and
be willing and able to comply with the requirements of RevAssist®.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
and again within 24 hours of prescribing lenalidomide (prescriptions must be filled
within 7 days) and must either commit to continued abstinence from heterosexual
intercourse or begin TWO acceptable methods of birth control.

- No contraindication to anticoagulation

Exclusion Criteria:

- Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking lenalidomide).

- Concurrent use of other anti-cancer agents or treatments.

- Known seropositive for or active viral infection with human immunodeficiency virus
(HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are
seropositive because of hepatitis B virus vaccine are eligible.

- History of thromboembolic event within the last 3 months

- Known hypersensitivity to any component of Avastin